Actos Bladder Cancer Lawsuits Notice

Actos Bladder Cancer Lawsuits : The incidence of bladder cancer has risen over the past 20 years. Currently, around 54 500 new cases of bladder cancer are diagnosed in the USA each year, and 15 000 cases in the UK. Bladder cancer is the fourth most common cancer in men in the USA and the tenth most common in women. It is one of the most frequent causes of cancer death, accounting for about 10 000 deaths annually in the USA and 5000 in the UK.

More information on Actos Bladder Cancer Lawsuits

The incidence of bladder cancer varies among different patient groups. For example, there is a 3:1 male-to-female ratio, though the prevalence among women appears to be rising.

The incidence is higher in elderly populations, with a median age at presentation of 60-65 years. No evidence exists for a familial or inherited pattern among any patient group, although occasional family clusters have been recorded. In black people the incidence is lower than in white people; in Asian races it appears to be intermediate. The lifetime risk of developing bladder cancer is:

  • 2.8% for white men
  • 0.9% for black men
  • 1.0% for white women
  • 0.6% for black women.

Information from other sources on Actos Bladder Cancer Lawsuits

Five-year survival for both black and white people during the period 1986-92 (60% and 82%, respectively) was significantly better than the equivalent rates for 1974-76 (47% and 74%, respectively; p < 0.05). It is not really known why there are substantial ethnic differences in incidence and prognosis, although putative factors include differences in diet and nutritional status, differences in gene expression (especially of enzymes that may metabolize carcinogens) and differential access to healthcare.

Our use of the term or terms Actos Bladder Cancer Lawsuits is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on (keyword) visit our site often.

Actos Bladder Cancer Lawsuits

Actos Bladder Cancer Lawsuits Updates

Actos Bladder Cancer Lawsuits : Although the relationship between squamous cell carcinoma of bladder and schistosoma infection is well established, currently the trends of BC in endemic zones, as Egypt, are changing. In fact, data from the largest tertiary cancer hospital in Egypt, NCI Cairo, were analyzed to verify the incidence of squamous cell carci­noma in the area. Data from 1980 to 2005 were obtained and data from 2778cases were available for analyses. The authors demonstrated a statically significant asso­ciation between period of diagnoses and histopathological type. In this way, patients diagnosed in 2005 had a sixfold higher odds associated to transitional cell carcinoma compared to those patients diagnosed in 1980 (Felix et al. 2008). Bilharzias associa­tion dropped from 82.4% to 55.3% and there was a significant increase of transi­tional cell carcinoma from 16% to 65%, while squamous cell carcinoma was less frequent, from 76% to 28%. Intimately related to this, there was an increase in the median age of patients from 47 to 60 years. The decline in the frequency of BC is related to a decline in bilharzias egg positivity in the specimen and this suggests a better control of the endemic disease in rural population (Gouda et al. 2007).

 

More information on Actos Bladder Cancer Lawsuits

Even though association between inflammation in schistosoma infection and squamous BC is well established, the role of inflammation due to other infections in the origin of BC, even transitional cell carcinoma, is less clear.Of the epidemiologic studies regarding urinary tract infection (UTIs) and BC, including transitional cell carcinoma, with one exception (Kjaer et al.1989), all the retrospective observational studies have demonstrated a positive association between BC and UTIs. Relative risk in these studies range between 1.4 and 16 for any history of urinary infection versus none, and similar associations have been found in men and women. To date no prospective study has been conducted to clearly establish the role of infection in bladder carcinogenesis.

 

Information from other sources on Actos Bladder Cancer Lawsuit

The most recent report stated that 222 BCs were diagnosed between 1950 and 1997. The excess relative risk was higher for women although not sig­nificant. Contrary to other cancers the risk was constant over age (Hall 2008). Similar findings have been shown in studies of secondary cancers in patients treated with high dose radiotherapy. For example, incidence of bladder cancer was compared among 243082 men who underwent therapy for prostate cancer between 1988 and 2003. The patient cohort was identified in the Surveillance, Epidemiology and End Results database (SEER) in United States. Of these 109,178 (45%) were submitted to radical prostatectomy, 93,059 (38%) to external beam radiotherapy (EBRT), 22,889 (9%) to brachytherapy, and 17,956 (7%) to combination of ERBT-BT. Median follow-up was 49 months. The relative risk of BC developing after EBRT, BT, and ERBT-BT compared to radical prostatectomy was 1.88, 1.52, and 1.85, respectively. Compared to the general US population, the standardized incidence ratio (SIR) for BC developing after RP, ERBT, BT, and ERBT-BT was 0.99, 1.42, 1.10, and 1.39, respectively. The increased risk of BC of patients sub­mitted to ERBT, BT, or combination must be taken into account during follow-up of patients, and considering that BC requires longer to develop, patients treated with radiation at young age are at highest risk and should be followed closely (Nieder et al. 2008).

 

Our use of the term or terms Actos Bladder Cancer Lawsuits is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer Lawsuits visit our site often.

http://www.seedol.com

Actos Bladder Cancer Lawsuits News

Actos Bladder Cancer Lawsuits : In the same way, the incidence of secondary malignancies using data from 104,760 1-year survivors of cervical cancer reported to 13 population-based cancer registries in Denmark, Finland, Norway, Sweden, and the United States has been published . Patients with cervical cancer treated with radiotherapy, but not those who did not receive radiotherapy, were at increased risk for all second cancers and cancers at heavily irradiated sites (colon, rectum/anus, urinary bladder, ovary, and genital sites), beyond 40 years of follow-up compared with women in the general population. The association of RT with second cancer was modified by age at cervical cancer diagnosis. The 40-year cumulative risk of any second cancer was higher among women diagnosed with cervical cancer before age 50 (22.2%, 95% CI = 21.5%-22.8%) than among women diagnosed after age 50 (16.4%, 95% CI = 16.1%-16.9%) (Chaturvedi et al. 2007).

 

More information on Actos Bladder Cancer Lawsuits

Several dietary factors had been related to BC, however the results of several studies were controversial and currently there is no sufficient evidence but a limited evidence of a cause relationship between BC and dietary factors. Despite this, several researchers had pointed out that a small part of BC cases would be influ­enced by dietary habits and that those factors must be considered.The Netherland Cohort Study on diet and cancer (NLCS) was initiated in 1986 with 120,852 men and women aged 55-69 years. Based on regional cancer regis­tries in the Netherlands and with the national pathology register (PALGA) the authors established the follow-up for BC incidents . Between 1986 and 1992, 619

 

Information from other sources on Actos Bladder Cancer Lawsuits

In their analysis, the authors did not find that total fluid intake was related to BC risk. However, they demonstrated a small correlation between alcohol consumption and BC in men, which was independent of the stage of tumor. That relationships was not confirmed in BC in women .On the other hand, they concluded that high consumption of total fruit was probably associated with small decrease in BC risk as well as they established a negative association between BC and selenium intake (Zeegers et al. 2004).With opposite results, it was reported by The Health Professionals Follow-up Study, which is, as well as NLCS, a prospective cohort study. It started in 1986 with 51,529 male health professionals aged 40-75 years from all 50 states of the United States. Of these 47,909 men were eligible for follow-up, and the follow-up rate averaged at 94% per follow-up cycle during the five biennial cycles between 1986 and 1996. They diagnosed 252 new cases of BC, and age and smoking were the two major risk factors related to cancer. Interestingly, and contrary to NLCS, they found that daily water consumption had a protective effect in risk of BC. In that way, when fluid intake was considered as a continuous variable the risk of BC decreased by 7% for every increment of 240 mL in daily fluid intake.

 

Our use of the term or terms Actos Bladder Cancer Lawsuits is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer Lawsuits visit our site often.

http://www.seedol.com

Actos Bladder Cancer Lawsuits

Actos Bladder Cancer Lawsuits : An intravenous pyelogram, or IVP, is a test used to define the anatomy of your urinary tract using intravenous dye and an x-ray machine. Doctors order this test to determine whether or not there are any blockages or tumors in the renal pelvis, ureter, or bladder. Often, patients are asked to have a light meal the night before an IVP and to skip break­fast the morning of the exam. You may be given instruc­tions to perform a bowel prep using magnesium citrate, a laxative available in your local pharmacy or supermarket, This clears out your small intestine and colon as these may interfere with visualization of your urinary tract. If you have diabetes and are using Glucophage (metformin), you may need to stop these medications several days in ad­vance. This should be coordinated by your urologist and primary care physician.

 

More information on Actos Bladder Cancer Lawsuits

There are several reasons why you should not have an IVP performed, and these will be explained by your doctor. If you have an allergy to IV dye, you could have a potentially severe allergic reaction. In some cases, steroids are given to prevent this from occurring. Either way, this is some­thing that must be discussed with your doctor before the exam. If you have abnormal kidney function, another test will most likely be performed instead of an IVP. This is because the IV dye can worsen your kidney function. If you are pregnant, another test will be performed because of the potentially small risk that the radiation from the x-ray machine poses to the developing fetus. If you have asthma, multiple myeloma, sickle cell disease, pheochromocytoma, or a tumor of your adrenal gland, your physician may order another test because you may also be at greater risk of com­plications from the exam.

IVP pros include its ability to assess how well your kidneys are working and the images that it can obtain of your renal pelvis and ureter. Its cons include x-ray radiation exposure in addition to the risks of an allergic reaction to IV contrast and potential worsening of borderline kidney function. IVPs are still ordered to evaluate people with blood in their urine or a diagnosis of bladder cancer, but it is slowly be­ing replaced by other, more accurate imaging modalities including CT scan and MRI.

Information from other sources on Actos Bladder Cancer Lawsuits

A CT, or CAT scan, is a computed tomographic scan that ob­tains accurate, detailed images of the body and its contents. It allows radiologists to look at detailed images of all your internal organs, including your heart, lungs, liver, brain, kidneys, and bladder, in addition to soft tissues like lymph nodes. CT scans are performed in radiolog)’ departments by radiologists with the assistance of nurses and technicians. The actual exam may only last 15 minutes, but you may be in the radiolog)’ area for an hour. As with the preparation for an IVP, you wall be asked to eat a light dinner the night before, and some doctors prefer bowel preparation with a laxative the day before. You should not eat anything in the 8 hours before your scheduled appointment. Those with diabetes using Glucophage must stop taking these medica­tions several days before die scan if IV dye will be used and will not be able to resume use of these medications for 48-72 hours after the scan. This is because of a potential harmful reaction from the medications and IV dye. Some physicians prefer that this exam be done after drinking a chalky oral dye to better differentiate your intestine from parts of your uri­nary tract. The pros of CT include the detailed images that it provides in addition to the relatively short amount of time it takes to perform the exam. Its cons are the risk of radiation exposure to the developing child in a pregnant woman and risk of an allergic reaction to IV dye.

 

Our use of the term or terms Actos Bladder Cancer Lawsuits is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer Lawsuits visit our site often.

http://www.seedol.com